Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBIT (2021 - 2025)

Historic EBIT for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $41.4 million.

  • Krystal Biotech's EBIT rose 8411.36% to $41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.2 million, marking a year-over-year increase of 47536.74%. This contributed to the annual value of $65.7 million for FY2024, which is 15987.13% up from last year.
  • Per Krystal Biotech's latest filing, its EBIT stood at $41.4 million for Q3 2025, which was up 8411.36% from $39.3 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's EBIT registered a high of $41.4 million during Q3 2025, and its lowest value of -$50.2 million during Q1 2022.
  • Its 5-year average for EBIT is -$7.4 million, with a median of -$15.7 million in 2021.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 24990.59% in 2022, then skyrocketed by 121682.6% in 2024.
  • Over the past 5 years, Krystal Biotech's EBIT (Quarter) stood at -$21.9 million in 2021, then crashed by 58.95% to -$34.8 million in 2022, then skyrocketed by 109.02% to $3.1 million in 2023, then surged by 1216.83% to $41.3 million in 2024, then grew by 0.13% to $41.4 million in 2025.
  • Its EBIT was $41.4 million in Q3 2025, compared to $39.3 million in Q2 2025 and $36.2 million in Q1 2025.